CoChat

Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes

Open access
Hofland, Tom, de Weerdt, Iris, ter Burg, Hanneke, de Boer, Renate, Tannheimer, Stacey, Tonino, Sanne H, Kater, Arnon P, Eldering, Eric · 2019 · The Journal of Immunology

The DOI matches its Crossref record; 48 of the 50 references it cites were found in a registry or an index.

Abstract

Despite the emergence of small molecule inhibitors, current treatment strategies for chronic lymphocytic leukemia (CLL) are not curative, and the search for new therapeutic modalities continues. Prosurvival signaling derived from the microenvironment is often mediated via JAK signaling. However, whether JAK inhibitors are useful in CLL therapy has not been studied extensively. JAK inhibitors are valuable therapeutic agents in myelofibrosis and show promising results in graft-versus-host-disease. However, JAK inhibition is associated with an increased infection risk, presumably because of the effect on other immune cells, a feature shared with other kinase inhibitors used for CLL treatment, such as the BTK inhibitor ibrutinib and the PI3Kδ inhibitor idelalisib. We compared functional effects of the JAK1/2 inhibitors momelotinib and ruxolitinib, the BTK inhibitors ibrutinib and tirabrutinib, and PI3Kδ inhibitor idelalisib on malignant CLL cells but also on healthy human T, B, and NK lymphocytes. We found several interesting differences among the inhibitors, apart from expected and well-known effects. Momelotinib but not ruxolitinib blocked cytokine-induced proliferation of CLL cells. Momelotinib also reduced BCR signaling, in contrast to ruxolitinib, indicating that these JAK inhibitors in fact have a distinct target spectrum. In contrast to tirabrutinib, ibrutinib had inhibitory effects on T cell activation, probably because of ITK inhibition. Remarkably, both BTK inhibitors stimulated IFN-γ production in a mixed lymphocyte reaction. Collectively, our results demonstrate that kinase inhibitors directed at identical targets may have differential effects on lymphocyte function. Their unique profile could be strategically employed to balance desired versus unwanted lymphocyte inhibition.

Overview

Integrity signals

Registry

Crossref · 10.4049/jimmunol.1900321

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 48 references

Cited by

Metadata

Authors
Hofland, T., de Weerdt, I., ter Burg, H., de Boer, R., Tannheimer, S., Tonino, S. H., Kater, A. P., & Eldering, E.
Affiliations
  • Amsterdam University Medical Centers (NL)
  • Department of Experimental Immunology, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam , 1105 AZ Amsterdam ,
  • Gilead Sciences (United States) (US)
Corresponding author
  • Hofland, Tom
  • Eldering, Eric
Venue
The Journal of Immunology
Published
2019-10
Volume
203
Issue
8
Pages
2100-2109
ISSN
  • 0022-1767 (ISSN-L)
  • 1550-6606
OpenAlex
W2973205945
Cited by
21
References
50
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2022: 6 · 2021: 6 · 2020: 4 · 2019: 1
FWCI
2.33
Type
journal article
Language
en
Open access
Locations
  • The Journal of Immunology (publishedVersion)
  • PubMed (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
Keywords
chronic lymphocytic leukemia, JAK inhibitors, BTK inhibitors, momelotinib, ruxolitinib, ibrutinib, tirabrutinib, idelalisib, B cell receptor signaling, T cell activation, IFN-gamma production, lymphocyte proliferation, infection risk
MeSH terms
Agammaglobulinaemia Tyrosine Kinase, Adenine, Animals, Antineoplastic Agents, Benzamides, Cell Survival, Humans, Imidazoles, Lymphocytes, Nitriles, Piperidines, Purines, Pyrazoles, Pyrimidines, Leukemia, Lymphocytic, Chronic, B-Cell, NIH 3T3 Cells, Protein Kinase Inhibitors, Cell Proliferation, Mice, Quinazolinones, Janus Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.